David Morris, MD
Urology · Hendersonville, TNNPI 1194841452
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $570,064 of the $871,148 with a category attached, or 65.4%. 60 manufacturers reported payments, led by Bayer at 26.7% of the total. Among urology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,856 payments — averaging $469.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$232K
- Johnson & Johnson$139K
- Astellas Pharma US Inc$132K
- AstraZeneca$105K
- SN Holdings, LLC$39K
- Pfizer$36K
- plus $187K from 54 others
Across 816 payments — averaging $7924.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.8M
- Janssen Research & Development, LLC$1.5M
- Merck$1.2M
- Clovis Oncology, Inc.$724K
- AstraZeneca$488K
- Bayer$190K
- plus $625K from 12 others
What the payments were for
- Consulting fees$185,55821%
- Speaking & faculty fees$570,06465%
- Travel & lodging$71,4478%
- Food & beverage$43,7425%
- Education$3380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$871,148 in reported general payments places this provider in the 95th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 311 | $4,386,172 |
| XtandiEnzalutamide | 322 | $4,284,938 |
| NubeqaDarolutamide | 110 | $1,408,342 |
| OrgovyxRelugolix | 492 | $1,258,155 |
| Abiraterone Acetate | 321 | $715,173 |
| MyrbetriqMirabegron | 320 | $205,274 |
| GemtesaVibegron | 136 | $76,341 |
| Solifenacin Succinate | 370 | $29,154 |
| Tamsulosin Hcl | 1,141 | $16,530 |
| Finasteride | 686 | $11,126 |
| XyostedTestosterone Enanthate | 12 | $7,159 |
| Testosterone | 34 | $5,978 |
| Estradiol | 87 | $5,652 |
| PremarinEstrogens, Conjugated | 11 | $4,567 |
| Testosterone Cypionate | 157 | $4,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $132,394 | $4,490,212642 claims |
| Johnson & JohnsonErleada | $138,955 | $4,386,172311 claims |
| BayerNubeqa | $232,162 | $1,408,342110 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $10,962 | $1,334,496628 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $10,321 | $715,173321 claims |
| Antares Pharma, Inc.Xyosted | $96 | $7,15912 claims |
| PfizerPremarin | $36,376 | $4,56711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 urology providers in Tennessee.
Other urology in Hendersonville
- L KnollNashville$2.1M
- David GubinMemphis$1M
- Gautam JayramNashville$1M
- Roger DmochowskiNashville$763K
- Paul EberGermantown$476K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$339K
- Melissa KaufmanNashville$312K
- Mark GreenbergerMemphis$249K
- Sam ChangNashville$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.